The clinical characteristics of patients with colistin-resistant Acinetobacter baumannii bacteraemia have been documented, but those of patients with bacteraemia caused by other Acinetobacter species remain unknown. Previous exposure to colistin has been shown to be associated with the emergence of colistin resistance, but may be not the only predisposing factor. In the current study, we highlight the risk and outcome of patients without previous exposure to colistin who acquired colistin-resistant Acinetobacter nosocomialis (ColRAN) bacteraemia. This 11-year single-centre retrospective study analysed 58 patients with ColRAN bacteraemia and 213 patients with colistin-susceptible A. nosocomialis (ColSAN) bacteraemia. Antimicrobial susceptibilities were determined with an agar dilution method. The clonal relationship of ColRAN isolates was determined with pulsed-field gel electrophoresis. A conjugation mating-out assay was conducted to delineate the potential transfer of colistin resistance genes. Multivariable analysis was performed to evaluate the risk factors for ColRAN bacteraemia. Chronic obstructive pulmonary disease (COPD) was independently associated with ColRAN bacteraemia (OR 3.04; 95% CI 1.45-6.37; p 0.003).
Introduction
Acinetobacter species have emerged as significant pathogens associated with severe nosocomial infections [1] . Acinetobacter baumannii and Acinetobacter nosocomialis, the most clinically significant species, together account for >80% of all Acinetobacter infections in Taiwan [2] [3] [4] . Although these two species cannot be distinguished by typical phenotypic methods used in clinical laboratories, they show significant differences in terms of susceptibility to antimicrobial agents and prevalence in epidemics [2] [3] [4] [5] .
The increasing worldwide prevalence of drug resistance, including carbapenem resistance in Acinetobacter species [1, 3, 4, 6] , has made colistin an important therapeutic option for infections involving carbapenem-resistant Acinetobacter species [7] [8] [9] . Inappropriate colistin use, however, has led to the development of colistin-resistant A. baumannii (ColRAB) [8] [9] [10] and colistin resistance in other Gram-negative bacteria [11, 12] . Several studies have documented the clinical characteristics of patients with ColRAB infection [9, 11] . In contrast, the risk factors and clinical impact of colistin-resistant A. nosocomialis (ColRAN), which is more prevalent than ColRAB [3, 4, 13, 14] , remain unknown. In the current study, we investigated the risks and outcomes of patients acquiring ColRAN bacteraemia without previous exposure to colistin. We compared the characteristics of patients with ColRAN and colistin-susceptible A. nosocomialis (ColSAN) bacteraemia, and also examined the antimicrobial susceptibilities and clonal relationships of all ColRAN isolates.
Materials and methods
This retrospective study was performed at the Taipei Veterans General Hospital (T-VGH) during an 11-year period (1998-2008) . Data analyses were performed at the Tri-Service General Hospital (TSGH), National Defense Medical Centre. Colistin was not used at the T-VGH during the study period. The study protocol was approved by the T-VGH and TSGH Institutional Review Boards (approval numbers 2011-10-012IC and 2-101-05-074, respectively), with a waiver for informed consent because the study was retrospective.
Chart review was performed for patients who had at least one positive blood culture for A. nosocomialis with symptoms and signs of infection. For patients with two or more positive blood cultures, only the first blood culture was included. The source of infection was determined according to CDC guidelines [15] . Patients with polymicrobial bacteraemia (isolation of one or more microorganisms other than A. nosocomialis from blood during the same bacteraemia episode) were excluded. A bacteraemia case without a definite identified source was defined as primary bacteraemia. Patients aged <18 years and those with incomplete medical records were excluded.
Data collection
Medical records were reviewed to extract demographic and clinical information, including underlying diseases, admission to the intensive-care unit, duration of hospitalization, schedule and dose of antimicrobials, receipt of mechanical ventilation, and infectious foci. Chronic kidney disease was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m 2 . Neutropenia was defined as an absolute neutrophil count of <0.5 × 10 9 cells/L. Use of corticosteroids was defined as receipt of a corticosteroid at a dose greater than or equal to 10 mg per day of prednisolone for >5 days in the 4-week period prior to the onset of bacteraemia. Previous use of antibiotics was defined as antimicrobial therapy (intravenous or oral) within 4 weeks before onset of bacteraemia. Recent surgery was defined as operations performed within 4 weeks prior to the onset of bacteraemia. The severity of illness was evaluated according to the Acute Physiology and Chronic Health Evaluation II (APACHE II) score within 24 h before the onset of bacteraemia.
Appropriate antimicrobial therapy was defined as administration of at least one antimicrobial agent to which the causative pathogen was susceptible within 48 h after the onset of bacteraemia, with the approved route and dosage for the affected end organ(s). Antimicrobial therapy that did not meet this definition was considered to be inappropriate. Monotherapy with an aminoglycoside was considered to be inappropriate therapy.
Microbiological studies
Bacterial isolates were phenotypically identified as members of the Acinetobacter calcoaceticus-baumannii complex with the API ID 32 GN system or the Vitek 2 system (both from bioMérieux, Marcy l'Etoile, France). A. nosocomialis was identified by sequencing the 16S-23S ribosomal DNA intergenic spacer region [16] . Antimicrobial susceptibility testing was performed with an agar dilution method according to the guidelines of the CLSI [17] . Colistin resistance was defined by the presence of a MIC of at least 2 mg/L.
Molecular typing
The clonal relationship of clinical isolates was determined by pulsed-field gel electrophoresis (PFGE) [18] of ApaI-digested genomic DNA with the Bio-Rad CHEF-Mapper apparatus (Bio-Rad Laboratories, Hercules, CA, USA). Cluster analysis was performed with BioNumerics version 5.0 (Applied Maths, Sint-Martens-Latem, Belgium) and the unweighted pair-group method with arithmetic averages. The Dice correlation coefficient (tolerance: 1%) was used to analyse similarities between band patterns. Isolates were considered to be different pulsotypes if they had more than three DNA fragment differences and a similarity of <80% in dendrogram analysis.
Conjugation experiments
Conjugation experiments were performed to determine whether the colistin resistance genes can be transferred from ColRAN to A. baumannii and ColSAN [19] . For these experiments, we randomly selected four representative ColRAN isolates that were susceptible to imipenem and ceftazidime from different pulsotypes as donors, and one colistinsusceptible but imipenem-resistant A. baumannii (ColSAB) isolate and two ColSAN isolates that were resistant to ceftazidime as recipients. The mating-out assays were performed on Müller-Hinton agar plates, with the filter mating technique, at 37°C. Transconjugants were selected on brain-heart infusion agar plates that contained colistin plus imipenem or ceftazidime. Species identification of transconjugants was performed with multiplex PCR amplifications, as previously described [20] .
Statistical analysis
The chi-square test with Yate's correction or Fisher's exact test was used to compare discrete variables, and Student's t-test or the Mann-Whitney rank sum test were used to compare continuous variables. Univariate analyses were performed separately for each risk factor to determine the OR and 95% CI. All biologically plausible variables with p-values of 0.10 in the univariate analysis and present in at least 10% of the patients were included in the logistic regression model for multivariate analysis, which employed a backward selection process. A pvalue of <0.05 was considered to be statistically significant. All statistical analyses were performed with SPSS software, version 19.0 (SPSS, Chicago, IL, USA).
Results
During the 11-year study period, 891 patients at our institution experienced at least one episode of A. calcoaceticus-baumannii complex bacteraemia; of these, 348 patients (39.1%) also experienced at least one episode of A. nosocomialis bacteraemia. Of these 348 patients, we excluded 77 patients (22.1%) with polymicrobial bacteraemia. The remaining 271 patients were included in the final analysis. Table 1 compares the demographic and clinical characteristics of patients with ColRAN bacteraemia (n = 58, 21.4%) and ColSAN bacteraemia (n = 213, 78.6%). ColRAN bacteraemia was more strongly associated with infection in an intensive-care unit (75.9% vs. 47.9%, p < 0.001), longer duration of hospitalization before infection (56 vs. 37 days, p < 0.001), use of mechanical ventilation for >48 h (74.1% vs. 40.8%, p < 0.001), underlying chronic obstructive pulmonary disease (COPD) (32.8% vs. 11.7%, p < 0.001), and previous use of an antibiotic (65.5% vs. 41.3%, p 0.001). In contrast, ColSAN bacteraemia was more strongly associated with the use of chemotherapy (3.5% vs. 16 .4%, p 0.011). ColRAN bacteraemia was more likely to originate from pneumonia (69.0% vs. 40.9%, p < 0.001), whereas ColSAN bacteraemia was more likely to occur as primary bacteraemia (31.9% vs. 8.6%, p < 0.001). The disease severity (APACHE II score) was greater in patients with Col-RAN bacteraemia (21 vs. 18, p 0.007). The frequencies of appropriate antimicrobial therapy were 46.6% among patients with ColRAN bacteraemia and 52.1% among those with Col-SAN bacteraemia (p 0.453). Interestingly, the two groups did not differ significantly with respect to 14-day, 28-day and overall mortality. Furthermore, among patients with bacteraemic pneumonia, those infected with ColRAN and ColSAN had similar APACHE II scores, 14-day, 28-day and overall mortality (data not shown), and durations of mechanical ventilation use (32 vs. 32.5 days, p 0.278).
ColRAN bacteraemia was more strongly associated with the previous use of an antipseudomonal β-lactam (39.7% vs. 17.8%, p < 0.001; Table 2 ), but no other significant differences were observed. Multivariate analysis indicated that COPD (OR 3.04; 95% CI 1.45-6.37; p 0.003) was the only factor independently associated with ColRAN bacteraemia (Table 3) . ColRAN isolates were more resistant to all tested antimicrobial agents except for ciprofloxacin, and these differences were statistically significant (p < 0.05) for amikacin, gentamicin, ceftazidime, piperacillin-tazobactam, imipenem, and meropenem (Table 4 ). For these isolates, the MIC50 and MIC90 of colistin were 4 mg/L and 8 mg/L, respectively (data not shown).
We performed PFGE with a cluster analysis of all 58 Col-RAN isolates (Fig. 1 ). There were 16 pulsotypes (A-P), based on a threshold of 80% similarity. Pulsotypes A (n = 22) and L (n = 19) were the most common. The number of cases of ColRAN bacteraemia in each year is shown in Fig. 2 . Conjugation experiments failed to prove that colistin resistance genes could be transferred from ColRAN to ColSAB and ColSAN.
Discussion
The results of this study revealed significant differences between the clinical characteristics of patients with ColRAN and ColSAN bacteraemia and the antimicrobial resistance patterns of the ColRAN and ColSAN clinical isolates. In patients with no history of colistin exposure, COPD was the only clinical factor independently associated with ColRAN bacteraemia. PFGE analysis of all 58 ColRAN isolates disclosed the presence of 16 pulsotypes, and 41 (70.7%) of the isolates were found to be pulsotype A or L. Conjugation experiments failed to prove that colistin resistance could be transferred to ColSAB and ColSAN.
Colistin was introduced to Taiwan in September 2007, according to the Taiwan National Health Insurance Research Database (data not shown). Four of our patients acquired ColRAN after that time; none of them had been referred from other hospitals, but rather acquired the bacteria during hospitalization at the T-VGH. However, this does not confirm that the patients had not been exposed to colistin prior to their hospitalization. After exclusion of these four patients, the analysis revealed that COPD remained an independent factor associated with the acquisition of ColRAN bacteraemia in our study (data not shown).
Previous studies have proposed COPD as a risk factor for colonization and infection by non-fermenting Gram-negative bacilli and multidrug-resistant bacteria [21] [22] [23] [24] . Several factors might explain these observations, including the prior use of antibiotics [21] , use of mechanical ventilation [22] , use of steroids [23] , and impaired lung function [23, 24] . However, the present study indicated that previous antibiotic use, mechanical ventilation and steroid use were not independently related to the presence of ColRAN bacteraemia. In COPD patients, the deterioration of lung function is associated with chronic inflammation, impaired mucociliary clearance in the lower airways, impaired local immune response, and disruption of the lung parenchyma [23, 24] . Previous research has demonstrated that ColRAB isolates show significantly altered cellular morphology relative to ColSAB [25] , including lipopolysaccharide deficiency, which might compromise virulence [26] . Hospitalized patients with different comorbidities might be similarly exposed to ColRAN, but the impaired virulence of this bacterium might only allow it to colonize and cause bacteraemia in COPD patients with impaired lung immunity. It remains to be investigated whether ColRAN undergoes cellular morphology alterations, as previously described for ColRAB [8, 25] , to make it better able to colonize the lung parenchyma of COPD patients.
In our study, patients with ColRAN bacteraemia had more severe illness than patients with ColSAN bacteraemia. Similar proportions of patients in both groups received appropriate antimicrobial therapy. However, the two groups did not differ significantly in terms of mortality. Among the patients with bacteraemic pneumonia, those with ColRAN and ColSAN had similar mortality rates and durations of mechanical ventilation use. These findings are consistent with previous studies on ColRAB [10, 11] , and suggest that increased resistance to colistin does not affect the virulence of these species.
Inappropriate colistin use is a well-known cause of colistin resistance [7 -13] . To delineate the predisposing factors for the acquisition of ColRAN other than colistin use, we conducted this retrospective study. We found that previous antibiotic use or exposure to a select class of antipseudomonal agents was not independently associated with ColRAN bacteraemia. This result is concordant with previous studies on ColRAB [8 -11] .
There is no standard therapeutic guideline for the management of colistin-resistant Acinetobacter infections. Some studies have described the use of combination therapies, such as colistin-rifampicin or colistin-carbapenem, for the treatment of ColRAB infections [10, 27] . Previous research has indicated high susceptibility of ColRAB to ciprofloxacin [28] ; similarly, we found that all 58 ColRAN isolates were susceptible to ciprofloxacin. Further research is needed to elucidate the relationship between colistin resistance and ciprofloxacin susceptibility in Acinetobacter species.
According to our molecular epidemiological examination of ColRAN isolates, there was dissemination of two major clones (pulsotypes A and L) during the study period, but a hospital outbreak was less likely, as none of the isolates clustered within a short period of time. Non-baumannii Acinetobacter species, including A. nosocomialis, might be reservoirs or recipients of resistance determinants from A. baumannii. For example, the plasmid-borne bla OXA-82 gene, which contains the upstream insertion sequence ISAba1 that contributes to carbapenem resistance, is transmittable between A. baumannii and A. nosocomialis [19, 29] . However, our conjugation experiments showed that ColRAN isolates did not transfer colistin resistance to A. baumannii.
This study had limitations that are inherent to retrospective studies, including inconsistencies in patient care and variability in patient backgrounds. The large number of patients with A. nosocomialis bacteraemia was a major strength of this study. Another strength is our use of a multivariate analysis to assess clinical variables that were independently and significantly associated with ColRAN bacteraemia.
In conclusion, COPD was an independent risk factor for the acquisition of ColRAN bacteraemia in patients without previous exposure to colistin. Although ColRAN bacteraemia was associated with more severe illness than ColSAN bacteraemia, patients with these two infections had similar 14-day, 28-day and overall mortality.
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